Bob Gower Purchases 508,614 Shares of Ensysce Biosciences (NASDAQ:ENSC) Stock

Posted by on Aug 20th, 2026

Ensysce Biosciences, Inc. (NASDAQ:ENSC – Get Free Report) Director Bob Gower purchased 508,614 shares of the business’s stock in a transaction on Thursday, April 23rd. The stock was purchased at an average price of $0.48 per share, for a total transaction of $244,134.72. Following the acquisition, the director owned 516,740 shares of the company’s stock, valued at approximately $248,035.20. This represents a 6,259.09% increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Ensysce Biosciences Stock Performance

Shares of Ensysce Biosciences stock opened at $0.39 on Thursday. The stock has a market capitalization of $7.55 million, a PE ratio of -0.14 and a beta of 0.84. Ensysce Biosciences, Inc. has a 52 week low of $0.23 and a 52 week high of $2.75. The stock has a 50 day moving average price of $0.31 and a two-hundred day moving average price of $0.39.

Ensysce Biosciences (NASDAQ:ENSC – Get Free Report) last issued its earnings results on Thursday, August 13th. The company reported ($0.20) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.20). Ensysce Biosciences had a negative return on equity of 2,550.30% and a negative net margin of 280.53%.The company had revenue of $1.16 million for the quarter, compared to analyst estimates of $1.20 million. Research analysts forecast that Ensysce Biosciences, Inc. will post -1.27 EPS for the current year.

Hedge Funds Weigh In On Ensysce Biosciences

Hedge funds and other institutional investors have recently modified their holdings of the business. Adage Capital Partners GP L.L.C. lifted its holdings in Ensysce Biosciences by 100.4% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 149,711 shares of the company’s stock worth $138,000 after acquiring an additional 75,000 shares during the period. DRW Securities LLC grew its stake in Ensysce Biosciences by 42.4% in the 4th quarter. DRW Securities LLC now owns 98,481 shares of the company’s stock valued at $91,000 after purchasing an additional 29,336 shares during the period. Citadel Advisors LLC purchased a new position in Ensysce Biosciences during the 3rd quarter valued at about $34,000. Finally, Virtu Financial LLC purchased a new position in Ensysce Biosciences during the 3rd quarter valued at about $34,000. Hedge funds and other institutional investors own 5.63% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have weighed in on ENSC. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Ensysce Biosciences in a research note on Friday, July 17th. Wall Street Zen raised shares of Ensysce Biosciences to a “hold” rating in a research report on Saturday, August 8th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has an average rating of “Sell”.

Check Out Our Latest Stock Analysis on ENSC

Ensysce Biosciences Company Profile

(Get Free Report)

Ensysce Biosciences, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel prodrug therapies aimed at improving pain management and addressing opioid misuse. Leveraging its proprietary prodrug platform, the company designs drug candidates that convert into active pharmaceuticals through specific enzymatic action, providing controlled-release profiles and built-in abuse deterrence features.

The company’s lead product candidate, ENS100, is an investigational oral prodrug of hydrocodone engineered to reduce the potential for misuse and abuse compared to immediate-release opioid formulations.

Featured Articles

Receive News & Ratings for Ensysce Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ensysce Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.